Total Funding
53
61
Total FundingSeries B raised
Growth Score
-4 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
48098
Invectys Therapeutics is a biopharmaceutical company focused on the development of immunotherapy approaches to treat cancer.
- Pierre Langlade: CEO and Founder
- Simon Wain-Hobson: Co-Founder
About the Company
Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. It was founded in 2010 by Pierre Langlade Demoyen and Simon Wayne-Hobson and is based in Paris.
Invectys develops a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients.
This allows virtually all cancers to be targeted. Invectys focuses its efforts on two highly prevalent tumor antigens: the nearly-universal tumor antigen telomerase that is critical to uncontrolled cell growth, and the HLA-G immune checkpoint expressed in over 50% of cancers.
